COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,703 Articles (22,913 medRxiv, 8,790 bioRxiv)

Most recent first Previous |  Page 998: Articles 9971-9980  | Next

USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING
Karlowitz, R., Stanifer, M. L., Roedig, J., Andrieux, G., Bojkova, D., Smith, S., Kowald, L., Schubert, R., Boerries, M., Cinatl, J., Boulant, S., van Wijk, S. J.
10.1101/2022.02.01.478628 — Posted: 2022-02-02
Why SARS-CoV-2 Omicron variant is milder? A single high-frequency mutation of structural envelope protein matters.
Xia, B., Wang, Y., Pan, X., Cheng, X., Ji, H., Zuo, X., Li, J., Gao, Z.
10.1101/2022.02.01.478647 — Posted: 2022-02-02
CLEC5A and TLR2 are critical in SARS-CoV-2-induced NET formation and lung inflammation
Sung, P.-S., Yang, S.-P., Peng, Y.-C., Sun, C.-P., Tao, M.-H., Hsieh, S.-L.
10.1101/2022.02.01.478701 — Posted: 2022-02-02
Hospitalisation for COVID-19 predicts long lasting cerebrovascular impairment: A prospective observational cohort study
Tsvetanov, K. A., Spindler, L. R. B., Stamatakis, E. A., Newcombe, V. F., Lupson, V. C., Chatfield, D. A., Manktelow, A. E., Outtrim, J. G., Elmer, A., Kingston, N., Bradley, J. R., Bullmore, E. T., Rowe, J. B., Menon, D. K., the Cambridge NeuroCOVID Group, , the NIHR COVID-19 BioResource, , the Cambridge NIHR Clinical Research Facility, , the CITIID-NIHR BioResource COVID-19 collaboration
10.1101/2022.02.01.22270235 — Posted: 2022-02-02
Understanding of and Trust in the Centers for Disease Control and Prevention's Revised COVID-19 Isolation and Quarantine Guidance Among US Adults
Mishra, V., Dexter, J. P.
10.1101/2022.02.01.22270288 — Posted: 2022-02-02 Discussion: Offsite
The tryptophan catabolite or kynurenine pathway in COVID-19 and critical COVID-19: a systematic review and meta-analysis
Almulla, A. F., Supasitthumrong, T., Tunvirachaisakul, C., Abo Algon, A. A., Al-Hakeim, H. K., Maes, M.
10.1101/2022.02.01.22270268 — Posted: 2022-02-02
Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against native-like vaccine and delta variant spike trimers
Cheedarla, N., Verkerke, H., Potlapalli, S., McLendon, K. B., Patel, A. B., Frank, F., Damhorst, G. L., Wu, H., O'Sick, W. H., Graciaa, D., Hudaib, F., Alter, D. N., Bryksin, J., Ortlund, E. A., Guarner, J., Auld, S., Shah, S., Lam, W., Mattoon, D., Johnson, J. M., David, W., Dhodapkar, M. V., Stowell, S. R., Neish, A. S., Roback, J. D.
10.1101/2022.02.01.22270279 — Posted: 2022-02-02
Durability of Omicron-neutralizing serum activity following mRNA booster immunization in elderly individuals
Vanshylla, K., Tober-Lau, P., Gruell, H., Muenn, F., Eggeling, R., Pfeifer, N., Le, N. H., Landgraf, I., Kurth, F., Sander, L. E., Klein, F.
10.1101/2022.02.02.22270302 — Posted: 2022-02-02
Humoral response, associated symptoms and profile of patients infected by SARS-CoV-2 with taste or smell disorders in the SAPRIS multicohort study.
Ramillon, J., de Lamballerie, X., Robineau, O., Blanche, H., Severi, G., Touvier, M., Zins, M., Carrat, F., Lapidus, N.
10.1101/2022.02.01.22270250 — Posted: 2022-02-02
SARS-CoV-2 antibody seroprevalence in cancer patients on systemic antineoplastic treatment in the first wave of the COVID-19 pandemic in Portugal
Fernandes, G., Paixao, P., Brum, L., Padrao, T., Correia, J., Albuquerque, J., Pulido, C., Nave, M., Timoteo, T., Rodrigues, T., Costa, F., Passos-Coelho, J. L.
10.1101/2022.01.31.22270178 — Posted: 2022-02-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).